Here's why Bristol Myers quarter wasn't enough to change our view on the stock ⊕
The company's future hinges on the success of Cobenfy, the company's new schizophrenia drug.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Bristol Myers
since
auto-detected in 7 stories
37 days ago
4 months ago
We're lowering our price target on Bristol Myers as two key overhangs persist
Shares were down around 5% on Thursday afternoon despite a beat-and-raise quarter.
5 months ago
Our bottom 5 stocks for the first half of 2025 — and why we still own them
This is what it will take to for a turnaround in shares of Salesforce, Apple, Bristol Myers, DuPont and Danaher.
Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug
Cigna accused Bristol Myers Squibb of violating antitrust law by keeping generic versions of its blood cancer drug Pomalyst off the market to retain a monopoly.
6 months ago
Why the stock rally fizzled — plus, our latest thinking on Goldman and Bristol Myers
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
7 months ago
Why we're lowering our Bristol Myers price target despite an earnings beat, guidance raise
Shares of Bristol Myers Squibb fell modestly after the drugmaker's better-than-expected first-quarter results.
8 months ago
JPMorgan says own this drug stock. It's one Jim Cramer is itching to buy again
The Club remains optimistic about Bristol Myers and shares JPMorgan's enthusiasm about Cobenfy.
page 1 of 1